Cargando…

Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients’ Outcomes?

SIMPLE SUMMARY: Immunotherapy-based combinations represent the front-line standard of care for metastatic clear cell renal cell carcinoma (mccRCC) patients. These combinations lead to an overall survival improvement and a dramatic increase of complete response rate raising the question of possible c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thouvenin, Jonathan, Masson, Claire, Boudier, Philippe, Maillet, Denis, Kuchler-Bopp, Sabine, Barthélémy, Philippe, Massfelder, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913235/ https://www.ncbi.nlm.nih.gov/pubmed/36765750 http://dx.doi.org/10.3390/cancers15030793

Ejemplares similares

Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma
por: Masson, Claire, et al.
Publicado: (2023)

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
por: Guillaume, Zoé, et al.
Publicado: (2022)

Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions
por: Thouvenin, Jonathan, et al.
Publicado: (2021)

Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma
por: Nerich, Virginie, et al.
Publicado: (2014)

Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Lee, Ji Hyun, et al.
Publicado: (2023)

Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities
por: Debien, Véronique, et al.
Publicado: (2019)

Induced Remission of Metastatic Squamous Cell Carcinoma with an Immune Checkpoint Inhibitor in a Patient with Recessive Dystrophic Epidermolysis Bullosa
por: Khaddour, Karam, et al.
Publicado: (2020)

Tooth Engineering: Searching for Dental Mesenchymal Cells Sources
por: Keller, Laetitia, et al.
Publicado: (2011)

Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials
por: Zhuang, Tony Zibo, et al.
Publicado: (2022)

Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma
por: Chatwal, Monica Sheila, et al.
Publicado: (2023)

Ultrasonographic Pattern of Testicular Metastasis of Clear Cell Renal Cell Carcinoma with Pathological Correlation
por: Libert, Florent, et al.
Publicado: (2016)

Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma
por: Lang, Hervé, et al.
Publicado: (2016)

Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix
por: Zong, Liju, et al.
Publicado: (2020)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities
por: Zarrabi, Kevin, et al.
Publicado: (2021)

Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
por: Chakiryan, Nicholas H., et al.
Publicado: (2022)

Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients
por: Wang, Qinchuan, et al.
Publicado: (2019)

SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients
por: Li, Pengju, et al.
Publicado: (2020)

DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma
por: Bao, Yewei, et al.
Publicado: (2021)

A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
por: Yu, Eun-mi, et al.
Publicado: (2021)

Association of sleep quality and mucosal healing in patients with inflammatory bowel disease in clinical remission
por: Michalopoulos, George, et al.
Publicado: (2018)

Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study
por: Maugeais, Madeleine, et al.
Publicado: (2022)

Editorial: Identifying novel biomarkers in bladder cancer
por: Ecke, Thorsten H., et al.
Publicado: (2023)

Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data
por: Perez, Leanne, et al.
Publicado: (2022)

Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2023)

Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection
por: Rizell, Magnus, et al.
Publicado: (2020)

Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
por: He, Shengxiu, et al.
Publicado: (2023)

Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe
por: Malicki, Stanisław, et al.
Publicado: (2022)

A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
por: Palma dos Reis, Ana Filipa, et al.
Publicado: (2022)

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
por: Irani, Yazad D., et al.
Publicado: (2023)

Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
por: Yoshida, Takashi, et al.
Publicado: (2021)

A Novel Ferroptosis-Related Pathway for Regulating Immune Checkpoints in Clear Cell Renal Cell Carcinoma
por: Gao, Su, et al.
Publicado: (2021)

Construction and Validation of a Novel Immune Checkpoint-Related Model in Clear Cell Renal Cell Carcinoma
por: Fan, ZhiXiang, et al.
Publicado: (2022)

Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC
por: Doppalapudi, Sai Krishnaraya, et al.
Publicado: (2021)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma
por: Aicher, Alexandra, et al.
Publicado: (2022)

Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma
por: Jee, ByulA, et al.
Publicado: (2022)

Editorial: in vitro and in vivo non-clinical models of kidney cancers
por: Dormoy, Valérian, et al.
Publicado: (2022)

Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
por: Xu, Kevin Y, et al.
Publicado: (2015)

Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients
por: Yao, Jiannan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qnah99up9eo29foq7grrt91oul